Edesa Biotech Licensing Deal with Kyorin Pharmaceutical Co., Ltd. Worth $146M
Edesa Biotech granted Kyorin Pharmaceutical an exclusive license to develop and commercialize its anti-TLR4 monoclonal antibody, paridiprubart (EB05), for the treatment of ARDS in Japan. Edesa receives a $12 million upfront payment and is eligible for up to $134 million in development, regulatory, and sales milestones, plus tiered double-digit royalties. Kyorin will fund all development and commercialization activities in Japan while Edesa retains rights in all other territories.
- Value
- $146M
- Counterparty
- Kyorin Pharmaceutical Co., Ltd.
- Term
- 15 years